← Back to All Filings

Voyager Therapeutics Director Sells $46k in Stock for Tax Purposes

Low SignificanceFebruary 10, 2026 at 4:27:05 PM EST

Voyager Therapeutics, Inc.

$VYGR144CIK: 0001640266

Subscribe to track VYGR

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Voyager Director Sells $46k in Stock for Tax Purposes

Company: Voyager Therapeutics, Inc. (VYGR) Form: 144 | Filed: 2026-02-10 Significance: Low

Insider: Alfred W. Sandrock Jr Title: Officer | Relationship: Director, Officer

Transaction: • Type: Sale (Proposed) • Shares: 12,192 • Price: ~$3.78 • Value: $46,093 • Owned After: Not Disclosed

Key Insight: This is a minor "sell-to-cover" transaction to meet tax obligations from a vested equity award. It is a non-discretionary sale and generally does not reflect a change in the insider's outlook on the company.

Comprehensive Analysis

SEC Filing Analysis: Voyager Therapeutics, Inc. (VYGR)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: An insider is proposing a minor sale of stock explicitly to cover tax liabilities arising from vested equity awards, a routine and non-discretionary action.
  • Market Impact: Negligible impact is expected due to the small size of the transaction and its non-discretionary nature.

Company Information

FieldValue
CompanyVoyager Therapeutics, Inc.
Ticker SymbolVYGR
CIK0001640266
IndustryBIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

FieldValue
NameAlfred W. Sandrock Jr
CIK0001577061
Title/PositionOfficer
RelationshipDirector, Officer

Transaction Details

FieldValue
Form Type144
Transaction Date2026-02-10 (Approximate Sale Date)
Transaction CodeN/A (Sale)
Security TypeCommon Stock
Shares Involved12,192
Price Per Share~$3.78
Total Value$46,093.08
Shares Owned AfterNot Disclosed
Ownership TypeNot Disclosed

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$46,093.08
% of Market Cap0.021%
Shares Transacted12,192
% of Shares Outstanding0.022%
Post-Transaction OwnershipNot Disclosed
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $220 million, this $46k transaction is financially immaterial.
  • Transaction Significance: The sale represents just 0.021% of the company's market cap and 0.022% of its shares outstanding, both far below any threshold of significance.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction is a "sell-to-cover" to satisfy tax obligations, not a discretionary sale reflecting insider sentiment. Its size is too small to influence the market.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The number of shares is a tiny fraction of typical daily trading volume.
  • Sentiment Indicator: Neutral. This type of filing is common and does not carry a bullish or bearish signal.

Additional Context

Transaction Notes

  • Special Circumstances: The filing remarks explicitly state, "Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution." This confirms the non-discretionary nature of the sale.
Topics:#SECFiling#InsiderTrading#VYGR#VoyagerTherapeutics#Form144#InsiderSell#StockMarket#Biotech

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.